April 19, 2018 - The National Post article "Good economics and good health: How Canada’s pharmaceutical companies make an impact" describes how pharmaceutical companies partner with academic institutions to expedite therapeutic discoveries. In its interview with Brad Wheeler of the University of British Columbia's University-Industry Liaison Office, the Vancouver Prostat
Three recent publications led by our Centre’s PIs describe discoveries in the development of prostate cancer and progression to castration-resistant disease. This information provides new targets for the development of potential therapeutics.
Discovery of non-canonical activation of Hh signalling
Dr. Lucia Nappi, a postdoctoral fellow working with Dr. Gleave at the VPC and clinical research fellow working with Drs. Kollmannsberger and Chi at the BCCA, has been awarded a 2018 Genitourinary Cancers Symposium Merit Award.
Yinan Li, a graduate student in Dr Xuesen Dong's lab, has won the Best...
Drs. Wyatt, Chi and their teams have a new Cancer Discovery publication, "Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer," in which they identify novel genomic biomarkers that could ultimately help decide whether patients with advanced prostate cancer should receive abiraterone or enzalutamide.
Vancouver Prostate Centre investigators were highly successful, receiving 6 Canadian Institutes of Health Research (CIHR) research grants in the Fall 2017 Project Grant competition for a total of $3.48 million over five years.
The funded projects are:
Read the original VCHRI News story here.
Dr. Martin Gleave was recently named a member of the Order of Canada, one of the country’s highest civilian honours, for his leadership role in developing new treatments for prostate cancer and for his research on the mechanisms involved in the development of treatment resistance in cancer.
Dr. Alex Wyatt has been awarded a 2017 CIHR Early Career Investigator Award. His project aims to develop a procedure that will enable the identification of metastatic bladder cancer patients most likely to respond to specific therapies. The funding partners are the Institute of Cancer Research and AstraZeneca Canada Inc., and the award is for $345,000 over 3 years.